C-RAD AB: Agreement with The Christie NHS Foundation Trust

Press release 2011-04-07

Agreement with The Christie NHS Foundation Trust, Manchester to clinically evaluate the C-RAD Sentinel system

C-RAD AB with its four fully owned subsidiaries are all active in the field of radiation therapy. C-RAD AB and The Christie in Manchester, Great Britain has signed an agreement to clinically evaluate the C-RAD Sentinel system.

The Christie, based in Manchester, is one of the largest cancer centers in Europe, treating more than 40,000 patients per year. Its radiotherapy department, based at its main site in south Manchester and in Oldham is one of the largest in the world. It opens another radiotherapy centre in Salford in July.

The Christie is also an international leader in cancer research and is home to countless world-firsts. It is part of the Manchester Cancer Research Centre with The University of Manchester and Cancer Research UK and is also one of seven partners in Manchester Academic Health Science Research Centre. Cancer research in Manchester has been officially ranked the best in the UK.

The C-RAD Sentinel system is a laser based surface scanning system that has been developed for use in radiation to accurately position the patient before treatment, to monitor the patient during the treatment and for so called respiratory gating.

The Christie’s Radiotherapy department will clinically evaluate the Sentinel system; this will be achieved by using the system on lung, esophagus and prostate patients. Results of this evaluation are planned to be published.

Erik Hedlund, CEO, C-RAD AB:

"At C-RAD we are full of expectations regarding the agreement with the The Christie’s radiotherapy department. The results of the studies will be of great importance for our further activities not just in Great Britain but also in the rest of Europe, North America and Asia. "

Libby Mills, Principal Radiographer; The Christie’s Radiotherapy department:

“We are looking forward to collaborating with C-RAD on this exciting project. The evaluation of this new technology is a great opportunity for The Christie radiotherapy team. We will be the first radiotherapy site in the UK to evaluate this equipment and assess potential benefits for our patients.''

For further information:

Erik Hedlund, CEO C-RAD AB, Telefon 018 - 66 69 31, E-post erik.hedlund@c-rad.se